701917-04-6

Basic information

• Product Name: 1H-Pyrazol-3-amine, 4-nitro-1-phenyl-
• CAS NO: 701917-04-6
• Molecular Formula: C9H8N4O2
• Molecular Weight: 204.188
• Mol File: 701917-04-6.mol

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazol-3-amine, 4-nitro-1-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazol-3-amine, 4-nitro-1-phenyl-(701917-04-6)
• EPA Substance Registry System: 1H-Pyrazol-3-amine, 4-nitro-1-phenyl-(701917-04-6)

Safety Data

• Hazardous Substances Data: 701917-04-6(Hazardous Substances Data)

Usage

Physical state

Yellow crystalline solid

Common uses

Building block for organic synthesis and pharmaceutical research, potential anti-inflammatory agent

Handling precautions

May pose hazards to human health and the environment if not properly handled and disposed of.

Upstream product

• 21443-84-5 ethyl 4-nitro-1-phenylpyrazole-3-carboxylate 
• 28663-68-5 ethyl (phenylhydrazono)chloroacetate 
• 62-53-3 aniline 
• 701917-02-4 4-nitro-1-phenyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 98-80-6 phenylboronic acid 
• 701917-03-5 4-nitro-1-phenyl-1H-pyrazole-3-carboxylic acid 

Downstream Products

• 936755-48-5 2-naphthyl {4-[({4-[(tert-butoxycarbonyl)amino]-1-phenyl-1H-pyrazol-3-yl}amino)carbonyl]benzyl}carbamate 
• 936755-55-4 tert-butyl {3-[(4-{1,1-difluoro-2-[2-(2-methoxybenzoyl)hydrazino]-2-oxoethyl}benzoyl)amino]-1-phenyl-1H-pyrazol-4-yl} carbamate 
• 936755-56-5 tert-butyl {3-[(4-{difluoro[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoyl)amino]-1-phenyl-1H-pyrazol-4-yl} carbamate 
• 936755-30-5 benzyl {4-[({4-[(tert-butoxycarbonyl)amino]-1-phenyl-1H-pyrazol-3-yl}amino)carbonyl]benzyl}carbamate 
• 936755-29-2 tert-butyl (3-{[4-(aminomethyl)benzoyl]amino}-1-phenyl-1H-pyrazol-4-yl)carbamate 
• 936755-47-4 pyridin-3-ylmethyl {4-[({4-[(tert-butoxycarbonyl)amino]-1-phenyl-1H-pyrazol-3-yl}amino)carbonyl]benzyl}carbamate 
• 936755-57-6 tert-butyl 4-(5-{[(4-nitro-1-phenyl-1H-pyrazol-3-yl)amino]carbonyl}pyridin-2-yl)piperazine-1-carboxylate 
• 936706-73-9 C₂₈H₂₇N₇O₅ 
• 913739-29-4 tert-butyl (3-amino-1-phenyl-1H-pyrazol-4-yl)carbamate 

Relevant articles and documents

HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

SUBSTITUTED NICOTINAMIDE COMPOUNDS

The present invention relates to a novel class of substituted nicotinamides. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplasti

PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS

The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differe

HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS

The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal

MODIFIED MALONATE DERIVATIVES

The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.

Spirocyclic compounds

The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of n

SUBSTITUTED NICOTINAMIDE COMPOUNDS

The present invention relates to a novel class of substituted nicotinamides.. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplast

FLUORINATED ARYLAMIDE DERIVATIVES

The present invention relates to a novel class of fluorinated arylamide derivatives. The instant compounds can be used to treat cancer. The fluorinated arylamide derivatives can also inhibit histone deacetylase and are suitable for use in selectively indu

BENZOTHIOPHENE DERIVATIVES

The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

NOVEL AZOLE DERIVATIVES

The present invention relates to a compound of the formula (I): wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, said methine being